6505--VA Phoenix and Tucson Radiopharmaceuticals IDIQ

Amendment / Modification

• Line Item Deletion: The line item for "Quadramet" has been removed from the solicitation's schedule.

• Period of Performance (PoP) Revision: The PoP is updated to a Base year plus Two option years. This change is reflected in the revised spreadsheet, "B.2 Price Cost Schedule – UPDATED v.3."

• New Submission Requirement: All previously submitted quotes are now invalid. Contractors must submit a new quote that incorporates these changes and acknowledges receipt of Amendment 0003.

• The solicitation's line item schedule.

• B.2 Statement of Work (regarding the Period of Performance).

• B.2 Price Cost Schedule (now updated as B.3 Price Cost Schedule - UPDATED v.3).

• A new quote submission is mandatory for all interested contractors, incorporating the changes from Amendment 0003.

• The response deadline is 02-20-2026 at 10:00 AM PACIFIC TIME, Los Angeles, USA.

Form / Attachment / Pricing Sheet

This document is an updated pricing schedule (version 3) for the opportunity. It details the estimated quantities and pricing for various radiopharmaceutical products over a base period and four option years (OY1, OY2). Bidders are expected to use this schedule to provide their pricing.

• Product List: Includes a variety of radiopharmaceuticals such as Tc99m Pertechnetate, Tc99m MDP, I-123 Capsules, I-131 Capsules, Xe-133, F-18 FDG, Ga-68 DOTATATE, and others.
• Estimated Quantities: Provides estimated quantities for each product for the base period.
• Pricing Columns: Includes columns for Base Pricing, Base Extended Cost, OY1 Pricing, OY1 Extended Cost, OY2 Pricing, and OY2 Extended Cost. All pricing fields are currently populated with 0.0, indicating that specific pricing needs to be filled in by the bidder.
• Totals: Includes rows for "Estimated Total Cost per Year" and "Estimated Total Contract Value for B+4," which are also currently populated with 0.0.

This pricing sheet is critical for bidders to understand the scope of products and estimated quantities required. Bidders must complete the pricing sections accurately to formulate their proposals. The zeroed-out pricing fields indicate that this is a template for bidders to fill in their proposed costs for each item and option year.

Form / Attachment / Pricing Sheet

This document is an updated "Price Cost Schedule" (version 2) for the opportunity. It outlines the estimated quantities and pricing structure for various radiopharmaceutical products over a base period and four option years.

• Product List: Details specific radiopharmaceutical items such as Tc99m Pertechnetate, Tc99m MDP, I-123 Capsules, Xe-133, F-18 FDG, and Ga-68 products, among others.
• Estimated Quantities: Provides the estimated quantity for each listed product.
• Pricing Columns: Includes columns for Base Pricing, Base Extended Cost, and pricing for four Option Years (OY1 to OY4) with their respective extended costs.
• Totals: Shows estimated total cost per year and estimated total contract value for the base period plus four option years.

Bidders are expected to fill in the pricing details for each item and period. The "Base Pricing" and "OYx Pricing" columns should be populated with unit costs, and the "Extended Cost" columns will be calculated based on the "Estimated Qty" and the respective pricing. All pricing fields are currently set to 0.0, indicating they require bidder input.

This pricing sheet is critical for bidders to understand the anticipated quantities of specific radiopharmaceuticals required and to formulate their cost proposals. It directly impacts the financial aspect of the bid and will be used for evaluating the cost-effectiveness of proposals submitted.

Amendment / Modification

This amendment (0002) to Solicitation/RFQ 36C26226Q0334 provides clarifications regarding F-18 DG dosage requirements. The participating VA Medical Centers require F-18 FDG in both multi-dose vial compatible with Bayer/MEDRED systems and unit dose forms.

• An updated B.3 Price/Cost Schedule (Version 2) is attached to this amendment. Bidders must use this updated spreadsheet when preparing their quotes.

• Bidders must review and use the updated B.3 Price/Cost Schedule (Version 2).

• Contractors are responsible for ensuring all calculations are accurate and maintaining the correct Excel format.

• Contractors may use their own quote format, but submissions must reflect the changes outlined in this amendment.

• All other terms and conditions remain unchanged.

Form / Attachment / Pricing Sheet

This document is an updated Excel spreadsheet containing a price and cost schedule for the opportunity. It lists various radiopharmaceutical products and their estimated quantities, with columns for base pricing and extended costs, as well as pricing for four option years (OY1-OY4).

• Description/Part Number: Lists specific radiopharmaceutical products such as Tc99m Pertechnetate, Tc99m MDP, I-123 Capsule, Xe-133, F-18 FDG, and others.
• Estimated Qty: The estimated quantity required for each item.
• Pricing Columns: Includes Base Pricing, OY1 Pricing, OY2 Pricing, OY3 Pricing, and OY4 Pricing.
• Extended Cost Columns: Corresponding extended costs for each pricing period.
• Totals: Provides an estimated total cost per year and an estimated total contract value for the base period plus four option years.

This document appears to be a template for bidders to fill in their pricing. Bidders should carefully review the listed items and quantities and provide their corresponding pricing for the base period and option years. The "Estimated Total Cost per Year" and "Estimated Total Contract Value" fields should be calculated based on the provided pricing.

This pricing sheet is critical for bidders to understand the cost structure of the opportunity and to prepare their proposals. It details the specific items and quantities the government anticipates procuring, allowing vendors to calculate their bid prices accurately. The inclusion of option year pricing indicates the potential for contract extension and associated costs over the full performance period.

Amendment / Modification

This amendment (0001) to Solicitation/RFQ 36C26226Q0334 makes the following changes:

• Removed VAAR Clause: VAAR clause 852.212-71, "Gray Market and Counterfeit Items," has been removed as the radiopharmaceuticals are not classified as medical supplies or equipment.

• Deleted Line Item: Line item 51, "Ra-224 Disochloride UD uCi (Xofigo)," has been deleted from the B.2 Price Cost Schedule.

• Updated Quantities: Quantities for requested radiopharmaceuticals have been updated. Contractors must use the attached B.2 Price Cost Schedule – UPDATED version for pricing.

• Clarified Order Thresholds: The minimum and maximum order threshold per delivery order has been clarified. This is an Indefinite Delivery Indefinite Quantity (IDIQ) contract where each station issues a delivery order with a one-year performance period. The minimum guaranteed purchase amount applies at the delivery order (PO) level, not per line item.

• VAAR clause 852.212-71

• B.2 Price Cost Schedule (Line Item 51 deleted, quantities updated)

• Solicitation text regarding minimum/maximum order thresholds and IDIQ structure.

Contractors must use the updated B.2 Price Cost Schedule for pricing. All other terms and conditions of the original solicitation remain unchanged.

Form / Attachment / Pricing Sheet

This document is a pricing schedule for various radiopharmaceutical products. It outlines estimated quantities and pricing structures for base and option years.

• Description/Part Number: Lists specific radiopharmaceutical products such as Tc99m Pertechnetate, Tc99m MDP, I-123 Capsules, Xe-133, and various kits.
• Estimated Qty: Provides the estimated quantity for each listed item.
• Base Pricing / Extended Cost: Columns for pricing and extended cost for the base contract period.
• OY1-OY4 Pricing / Extended Cost: Columns for pricing and extended cost for Option Years 1 through 4.
• Estimated Total Cost per Year / Total Contract Value: Summarizes the total estimated costs.

This document appears to be a template for providing pricing information. Bidders are expected to fill in the pricing details for each item and for each contract year (base and option years). The "Estimated Total Cost per Year" and "Estimated Total Contract Value" fields should be calculated based on the entered pricing and quantities.

This pricing schedule is critical for bidders to understand the expected cost structure for the radiopharmaceuticals required. Bidders must accurately complete this sheet to submit a compliant and competitive proposal. The quantities and the structure for base and option years will directly influence the overall bid price and the potential value of the contract.

Solicitation / RFP / RFQ

This is a combined synopsis/solicitation for commercial supplies, seeking a contractor to supply radiopharmaceuticals for the VA Phoenix and Tucson Healthcare Systems. The government intends to award a single, firm-fixed-price, Indefinite Delivery Indefinite Quantity (IDIQ) contract for a base period plus four option years.

• Supply of various radiopharmaceuticals as listed in the document.

• Shipping term is FOB Destination; shipping costs must be included in the unit cost.

• Contractor must be an Original Equipment Manufacturer (OEM), authorized dealer, distributor, or reseller, verified by an authorization letter.

• No remanufactured or gray market items will be accepted.

• Deliveries are required by 06:30 AM the next business day, with a potential for same-day delivery.

• Contractor must perform quality control and meet all relevant regulatory agency rules.

• Specific radiopharmaceuticals and estimated annual quantities are detailed in Section B.2.

• Contract Type: Firm-Fixed-Price IDIQ

• Period of Performance: Base (4/1/2026 – 3/31/2027) plus four option years (through 3/31/2031).

• Minimum Order Threshold per Delivery Order: $250,000.00

• Maximum Order Threshold per Delivery Order: $1,000,000.00

• Questions due by February 6, 2026, 10:00 AM Pacific Time via email to Hestia.Sim@va.gov.

• Quotes/Proposals due by February 13, 2026, 10:00 AM Pacific Time.

• Pricing must be submitted using the attached spreadsheet (B.3 Price Cost Schedule) or a mirrored format.

• Evaluation is based solely on price.

• This is an unrestricted, full and open competition.

• NAICS Code: 325412 (Radiopharmaceutical Production), Size Standard: 1,300 Employees.

• Offerors must be registered in www.sam.gov.

• VAAR 852.212-71 Gray Market and Counterfeit Items applies.

• The document references numerous FAR and VAAR clauses and provisions.